If HIV patients keep taking the injection for a full year, they lose even more belly fat inside their abdomen—about 18% total.

Scientific Claim

Continued use of tesamorelin (2 mg subcutaneous daily) for 12 months reduces visceral adipose tissue by approximately 18% in HIV-infected adults on antiretroviral therapy with abdominal fat accumulation, indicating sustained efficacy over time.

Original Statement

“VAT was reduced by approximately 18% (P < 0.001) in patients continuing tesamorelin for 12 months.”

From study:Unknown Title

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The 12-month data comes from a continuation of the RCT design with randomization and blinding, supporting definitive causal language.

Evidence from Studies

Supporting (1)

Unknown Title

Randomized Controlled Trial

Human

This study found that giving HIV patients a daily shot of tesamorelin for a year shrunk their belly fat by about 18%, and the fat came back when they stopped the shot — so the drug works if you keep using it.

Contradicting (0)

No contradicting evidence found

Source Study

Unknown Title

Score: 81

DOI: 10.1097/QAI.0b013e3181cbdaff

Similar Assertions

A daily injection called tesamorelin helps HIV patients on medication lose belly fat inside their abdomen, while a fake shot doesn’t.

96%

A drug called tesamorelin helps HIV patients with belly fat buildup lose about 11% of their dangerous internal belly fat in six months, while those on a dummy pill lose almost none.

94%

A drug called tesamorelin helps reduce belly fat deep inside the abdomen for people with HIV who are on medication, making their belly fat decrease by about 15% compared to those not taking the drug. This finding is from the abstract summary - full study details were not available

94%

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

93%

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

93%